Inclusion Criteria:

- Clinically diagnosed with essential tremor
- Mentally and physically capable of performing tasks on the mobile device
- Willing to discuss use of the software platform and perform questionnaires regarding the use of this software
- Willing to obtain care at an affiliated NTD research site (Johns Hopkins Univ.; Sibley Hospital)
- Ideally (Not Mandatory) the patient would be at an inflection point in their care:
    - ie: just diagnosed with ET, just started medicine or recently had a medication change (trying a new drug), considering surgery, recent change (worsening or improvement) in symptoms

Why is this research being done?

The purpose of this study is to evaluate the feasibility and clinical utility of using proprietary mobile software (NewTouch Digital, Inc.) to track symptom data of patients with movement disorders.

The hypotheses of this study include:

1. Patients will be able to easily and effectively use the New Touch Digital software platform on a mobile device
2. Tremor can be measured and quantified in an objective manner
3. Data regarding symptoms and medication use can be efficiently tracked over a continuous time period
4. Data can be visualized at discrete time intervals
5. Data collected from patients will be more consistent and objective over time than current non-digital methods
6. Data collected can be employed by clinicians to assist in making decisions about patient care

You are being asked to participate in this study because you are older than 18 years of age, have been diagnosed with a movement disorder and are seeing a neurologist as a standard part of your clinical care.

Up to 10 people will participate in this study.

How long will this study take?

Your participation in this study will occur over a six month period. Over these six months, there will be three separate follow-up sessions with your neurologist or licensed practitioner (LP) as well as four scheduled over-the-phone interviews (months 1, 2, 4, and 5) performed by team members from NewTouch Digital, Inc. In addition, you may be asked to participate in unscheduled interviews with the NTD team for follow-up and technical support.

1. The first session will involve completing the consent form and receiving the mobile device with pre-loaded NTD software. This will occur after your regular appointment. The NTDl staff will introduce you to the software and with a tutorial
2. The second in-person session will occur after three months. This will occur with your doctor or licensed practitioner. You will undergo a standard office visit. During the visit, you will be asked to complete a software platform questionnaire and will have an opportunity to meet with the NTD team for in-person discussion of experience using the software.
3. The third in-person session will occur at six months. This will be the final session. As with the second in-person session you will undergo a standard office visit. During the visit, you will be asked to complete a software platform questionnaire and will have an opportunity to meet with the NTD team for in-person discussion of experience using the software. You will also be provided with a debriefing by the NTD staff. The mobile device will be collected
4. In between in-person sessions (months 1,2,4,5) you will have monthly phone calls with the NTD staff. This will consist of a survey to determine usability of the mobile software

5. In addition, you may be asked to participate in unscheduled interviews with the NTD team for follow-up and technical support

What will happen if you choose to participate in the study?

Day 1 –
Consent, introduction and mobile device prescription
The patient will meet with NTD team and with participating LP. The LP will introduce the company and software and will offer enrollment to the patient if he/she determines that the patient is eligible to participate in the study. At this point the patient will be enrolled. Consent will be obtained once the NTD team has determined that the patient is able to perform basic mobile device commands. The NTD team will perform an orientation with the software and provide answers to any patient questions. The patient will also be briefed with expectations for the trial by the NTD team and the LP.

Month 1
Software platform questionnaire (telephone or email)
Survey to determine usability of software will be administered. Patients will be prompted about each section of the mobile platform (wellness survey, objective tasks and medication diary). Questions will elicit information about user experience and relevance of tasks to current disease states.

Month 2 (same as Month 1 above)
Software platform questionnaire (telephone or email)
Survey to determine usability of software will be administered. Patients will be prompted about each section of the mobile platform (wellness survey, objective tasks and medication diary). Questions will elicit information about user experience and relevance of tasks to current disease states.

Month 3
Patient visit with licensed practitioner
The patient will have a standard clinical visit with the LP. After the visit, the patient will undergo a software platform questionnaire and will have an opportunity to meet with the NTD team for in-person discussion of software platform issues such as bugs, features or usability.

Month 4, 5 (same as Month 1, 2 above)
Software platform questionnaire (telephone or email)
Survey to determine usability of software will be administered. Patients will be prompted about each section of the mobile platform (wellness survey, objective tasks and medication diary). Questions will elicit information about user experience and relevance of tasks to current disease states.

Month 6
Final visit, mobile device collection, final comments
As above during month 3. The patient and LP will be debriefed and mobile device will be collected.

In addition, you may be asked to participate in periodic unscheduled interviews with the NTD team for follow-up and technical support.